Combination of two compounds shows promise in the lab

Researchers from industry and academia will leverage new chemistry to hit difficult drug targets.

Compounds block a protein involved in many cancers by cementing it shut.

A diminutive protein prompts a closer look at DNA dark matter.

Experts call for significant changes to facilitate the discovery of new treatments.

New NIBR President Jay Bradner shares on drug discovery, his leadership style and what’s next for his career in biomedical research.

Researchers from Seattle Children’s and Novartis shed light on developmental brain disorders that lead to intractable epilepsy.

Novel PRC2 inhibitor changes the expression of hundreds of genes in lab model

Novartis collaborates with Homology Medicines to adapt and refine genome editing technology.

Immunotherapy for cancer is on the brink of breakthroughs. Learn how NIBR have high expectations for this medical science.

Team uncovers a potential therapeutic approach for patients deficient in a protein called Shank3.